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From January 2008 to April 2009, 72 cases of severe Clostridium 
difficile infection were reported from 18 different districts in the 
state of Hesse, Germany. A total of 41 C. difficile isolates from 41 
patients were subjected to PCR ribotyping. PCR ribotype (RT) 027 
was the most prevalent strain accounting for 24 of 41 (59%) of 
typed isolates, followed by RT 001 (eight isolates, 20%), RT 017 
and 042 (two isolates each), and RT 003, 066, 078, 081, and 
RKI-034 (one isolate each). Eighteen patients had died within 
30 days after admission. C. difficile was reported as underlying 
cause of or contributing to death in 14 patients, indicating a case 
fatality rate of 19%. The patients with lethal outcome attributable 
to C. difficile were 59-89 years-old (median 78 years). Ribotyping 
results were available for seven isolates associated with lethal 
outcome, which were identified as RT 027 in three and as RT 001 
and 017 in two cases each. Our data suggest that C. difficile RT 
027 is prevalent in some hospitals in Hesse and that, in addition 
to the possibly more virulent RT 027, other toxigenic C. difficile 
strains like RT 001 and 017 are associated with lethal C. difficile 
infections in this region.
Introduction
Clostridium difficile infection (CDI) is a major cause of 
morbidity and mortality from healthcare-associated infections 
in economically developed countries. CDI is primarily linked 
with hospital admission and prior antimicrobial treatment. The 
symptoms can range from mild diarrhoea to serious manifestations 
such as pseudomembranous colitis, toxic megacolon or perforation 
of colon [1]. In recent years, a hypervirulent strain, which has 
been characterised by pulsed field gel-electrophoresis as North 
American pulsed-field gel electrophoresis type 1 (NAP1) and by 
PCR as ribotype (RT) 027, has emerged in North America, Canada, 
and several European countries [2-6]. This strain has primarily 
been described in association with hospital outbreaks but may also 
cause community-acquired infection. RT 027 is characterised by 
production of C. difficile toxins A and B and a third toxin (binary 
toxin), deletions in the regulatory gene tcdC that potentially 
allow increased toxin A and B production, and resistance to new 
fluoroquinolones such as moxifloxacin [7,8].
In Germany, a hospital associated outbreak of the C. difficile 
RT 027 strain was reported in 2007 from Rheinland-Palatina in 
south-western Germany [9]. Since then, RT 027 has sporadically 
been isolated in other geographic regions of Germany [10]. A recent 
study found a high prevalence (55%) of C. difficile RT 001 in 
patients with C. difficile-associated diarrhoea (CDAD) in southern 
Germany [11]. Isolates corresponding to RT 001 did not contain 
the binary toxin genes cdtA and cdtB and displayed resistance to 
moxifloxacin and erythromycin [11].
In December 2007, a requirement for mandatory notification 
of severe CDI was introduced in Germany [12]. According to this 
requirement, severe CDI was defined as pseudomembranous colitis 
confirmed by endoscopy or histology, or CDAD or toxic megacolon 
with positive laboratory results for C. difficile associated with one 
of the following conditions:  
• readmission to the hospital because of recurrent CDI, 
• admission to intensive care unit because of CDAD or its 
complications, 
• abdominal surgery because of toxic megacolon, perforation or 
refractory colitis, 
• death within 30 day after CDAD, with CDI as underlying cause 
or contributing to death, 
• detection of RT 027. 
The Hesse State Health Office (HSHO) receives notifications on 
severe CDI from local health authorities of the state of Hesse, which 
is located in western Germany and has approximately six million 
inhabitants. Following the introduction of the federal notification 
requirement, we initiated a pilot study to characterise C. difficile 
isolates associated with severe CDI in Hesse by offering for free 
a complete microbiological diagnostic service including culture, 
toxin detection, antimicrobial resistance testing and ribotyping 
to those healthcare facilities in Hesse that do not have access to 
these analyses. In this report, we present the results of our study 
during the first 16 months after introduction of these measures.
Patients and methods 
Study population 
From January 2008 to April 2009, 60 patients with notifiable 
CDI were reported by local health authorities via electronic 
notification system (SurvNet) to the HSHO. A total of 24 
C. difficile isolates from 24 of these patients had been submitted 
by the microbiological laboratories of the respective hospitals to a 
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national reference laboratory for C. difficile (Institute for Medical 
Microbiology, University of Mainz, or Robert Koch Institute (RKI), 
Wernigerode, Germany) for ribotyping. The ribotyping results of 
these isolates were reported to HSHO along with the case reports 
and corresponded in 23 of 24 cases to RT 027.
In addition, we received 22 stool samples from 17 patients 
with severe CDI that were sent to the microbiological laboratory 
of HSHO for detection and molecular typing of C. difficile during 
the study period. Comparison of the electronic notification reports 
with the data of these 17 patients revealed that 12 of them had 
not been reported by the electronic notification system. These 
cases were additionally enrolled in this study. The 17 patients 
were hospitalised in 13 different hospitals. Seventeen isolates 
(one isolate per patient) were forwarded to the national reference 
laboratory at the RKI for PCR ribotyping. 
C. difficile culture, toxin analysis, and antimicrobial susceptibility 
testing
Faecal culture for C. difficile was performed on C. difficile-
selective agar containing cycloserine, cefoxitin, and amphotericin 
B (Bio Mérieux) under anaerobic conditions. Identification of 
C. difficile was performed by routine microbiologic techniques and a 
rapid confirmatory latex agglutination test for C. difficile (Microgen 
Bioproducts). Twelve of 17 C. difficile isolates that were isolated in 
the HSHO laboratories were tested for in vitro toxin production with 
an ELISA detecting toxin A and/or B (Biopharm). Of the remaining 
five cases, four had been tested positive for toxin A/B directly from 
the stool specimen and were therefore considered to be toxin-
positive. One isolate was lost because of fungal contamination 
and could not be used for ELISA or antimicrobial susceptibility 
testing. Sixteen isolates were subjected to susceptibility testing for 
erythromycin and moxifloxacin by E-test (AB-Biodisc).
PCR ribotyping
PCR ribotyping was performed at the RKI according the protocol 
of Bidet et al. [13], except that PCR Products were run on 1.5% 
agarose gels in 1× TBE at 85 volts for 4 h. Through cooperation 
with the reference laboratory for C. difficile at the Leiden 
University Medical Centre in the Netherlands and the German 
reference laboratory for gastrointestinal infections in Freiburg, 
the RKI accumulated a reference strain collection of 76 different 
C. difficile ribotypes, including 25 reference strains from the Cardiff 
Anaerobe Reference Laboratory in Wales, United Kingdom [14]. 
PCR ribotypes that differed from reference patterns by at least one 
band were assigned novel PCR ribotypes and marked with the prefix 
RKI [15]. Ribotyping at the University of Mainz was performed as 
described by Brazier et al. [6] by using the 25 reference strains 
from the Cardiff Anaerobe Reference Laboratory. 
Results 
Study population
From January 2008 to April 2009, a total of 72 severe CDI 
cases were reported to the HSHO by local health authorities or by 
clinicians in Hesse (Figure 1). 
Thirty-eight patients (53%) were male and 34 (47%) were 
female. The patients´ age ranged from 30 to 94 years with a median 
age of 80 years (Figure 2). 
The clinical symptoms included diarrhoea (72 cases), 
recurrent infection leading to hospital admission (19 cases), 
pseudomembranous colitis (nine cases), sepsis (five cases), colitis 
(two cases), and colon perforation, peritonitis and pancreatitis 
(one case each). Twenty-three of the cases were reported because 
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of detection of RT 027. The clinical outcome was disclosed in 
60 cases (86%). The infection was lethal within 30 days after 
diagnosis in 18 cases (25%). Infection by C. difficile was reported 
as underlying cause of or contributing to death in 13 cases, and in 
one case as the most probable cause of death. The patients with 
lethal outcome that could be attributed to CDI were between 59 
and 89 years-old, with a median age of 78 years.
PCR ribotypes, toxin production, antimicrobial susceptibility 
Ribotyping results were available for 41 isolates obtained from 
41 of the 72 patients with severe CDI. Twenty-four ribotyping results 
were reported to our institution via electronic notification system, 
while 17 isolates were isolated in the microbiological laboratory of 
our institution and forwarded for ribotyping to the national reference 
laboratory at the RKI. A total of 24 isolates were identified as RT 
027, eight isolates as RT 001, two isolates each as RT 017 and 
042, and one isolate each as RT 003, 066, 078 and 081. One 
isolate could not be assigned to any known RT and was designated 
as RKI-034 (Figure 3). 
Production of toxin A and/or B was assessed in culture 
supernatants of the 12 C. difficile isolates cultured in our institution 
from patients with severe CDI. All isolates were tested positive for 
toxin A and/or B production. Interestingly, direct toxin detection in 
stool samples was negative in four of these 12 cases, confirming 
the higher sensitivity of culture compared to direct toxin detection 
in stool samples. Antimicrobial susceptibility results were available 
for 16 isolates. Six of the eight RT 001 isolates were tested and 
displayed resistance to moxifloxacin and erythromycin. Both RT 
017 isolates, one of the two RT 042 isolates and the RT 078 isolate 
were resistant to moxifloxacin. Six isolates were susceptible to 
moxifloxacin. These results suggest that resistance to moxifloxacin 
is not a specific marker for RT 027.
Characterisation of C. difficile isolates associated with lethal 
infection
Eighteen (25%) patients had died during the hospitalisation 
period associated with severe CDI. Ribotyping results were available 
for seven of the cases with lethal outcome and identified RT 027 
in three cases and RT 001 and 017 in two cases each (Figure 
3). The clinical symptoms, previous antimicrobial therapy, and 
antimicrobial susceptibility results of these seven cases are 
summarised in the Table 1.
Discussion
In this study, we present the first results on surveillance of severe 
CDI in the state of Hesse with approximately six million inhabitants. 
A total of 72 cases of severe CDI were included in this study. 
Sixty cases were reported through the federal notification system, 
whereas 12 additional cases were enrolled because of our offer to 
analyse samples from patients with severe CDI in our diagnostic 
laboratory at no charge. Taking into account possible underreporting 
and the restricted use of microbiological diagnostic tools such as 
culture and ribotyping because of economic considerations, it can 
be hypothesised that the real incidence of severe CDI might be 
markedly higher in our region.
Sixty-nine (96%) of 72 patients included in this study were older 
than 60 years. The median age was 80 years. We observed a high 
rate (19%) of disease-related fatality in our study. Eleven of 14 
patients with lethal outcome that was attributable to CDAD were 
older than 70 years. This finding is in accordance with the results 
of a recent study that identified advanced age (over 70 years) as 
a significant risk factor for illness and death among patients with 
CDAD [16]. However, it can not be ruled out that the emergence 
and circulation of epidemic and highly virulent C. difficile strain(s) 
may have contributed to an increased case fatality rate in our study.
Nine different C. difficile ribotypes were associated with severe 
CDI in our study. Ribotypes 027 and 001 were the most prevalent 
strains, while all other ribotypes were encountered only once or 
twice. Twenty-four of 41 typed isolates (59%) were RT 027. Since 
detection of RT 027 represents a case definition criterion for severe 
CDI in Germany, the high proportion of RT 027 may at least partially 
be attributed to a sampling bias. However, since the majority of RT 
027 isolates were reported from a distinct district, a local outbreak 
in a particular hospital in that region can not be excluded. Further 
studies are required to evaluate this hypothesis. Taken together, 
our data show unequivocally that C. difficile 027 has emerged and 
is prevalent in Hesse.
Eight isolates (20%) were identified as RT 001 in this study. 
The high prevalence of RT 001 in our study is in accordance with 
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Patient 1, 83, f 9 Mar 2008 medicine CDAD, dialysis, hemi-colectomy, ceftriaxon, clarithromycin, 
imipenem
n.d. n.d. 027
Patient 2, 62, f 20 Mar 2008 medicine CDAD, colitis, peritonitis ceftriaxon, vancomycin, 
metronidazole
S R 017
Patient 3, 86, m 22 Jul 2008 medicine fracture, intracranial bleeding, 
dialysis, CDAD
ceftriaxon n.d. n.d. 027
Patient 4, 83, m 31 Jul 2008 medicine urinary tract infection, CDAD, 
colitis
ampicillin-sulbactam R R 001
Patient 5, 73, f 9 Sept 2008 geriatrics cystitis, CDAD, readmission levofloxacin, vancomycin n.d. R 027
Patient 6, 72, m 10 Oct 2008 urology gastroenteritis, CDAD unknown, metronidazole R R 017
Patient 7, 59, m 11 Dec 2008 medicine pseudomembranous colitis, sepsis clarithromycin, amoxicillin, 
ampicillin-sulbactam
R R 001
CDAD: Clostridium difficile-associated diarrhoea; n.d.: not defined; R: resistant; S: sensitive.
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the results of Borgmann et al. who found a high prevalence (55%) 
of RT 001 in patients with CDAD in southern Germany in 2008 
[11]. Thus, RT 001 appears to be a common C. difficile genotype in 
western and southern Germany. It is noteworthy that RT 001 used 
to be the most prevalent strain associated with hospital outbreaks 
in English hospitals in 2005, but its prevalence has declined to 
7.8% of isolates in 2007-2008 [6]. Future studies are necessary 
to follow up the distribution of this ribotype in Germany. 
One of the isolates in our study was identified as RT 078. An 
increased prevalence of CDI due to this ribotype in the Netherlands 
has been reported by Goorhuis et al. [17]. In the latter study, CDI 
due to both RT 078 and RT 027 presented with similar severity, 
but CDI associated with RT 078 affected a younger population 
and was more frequently community-associated. In our study, the 
patient suffering from severe CDI due to RT 078 was 60 years-old 
and therefore younger than the average. Our results indicate that 
RT 078 is prevalent in hospitals in Hesse. They are in agreement 
with the data by Rupnik et al. [18] who found RT 078 in 7.5% 
of C. difficile isolates collected from hospitals in Göttingen and 
the surrounding regions in the Lower Saxonia, Germany in 2006.
Ribotyping results were available for seven isolates associated 
with lethal CDI; three isolates were identified as RT 027, and two 
isolates each as RT 001 and 017. Our data suggest that, along 
with the hypervirulent RT 027, other toxigenic C. difficile strains 
such as RT 001 and 017 are associated with severe and lethal 
CDI in Hesse. It is noteworthy that ribotyping results were not 
available for half of the lethal cases of CDI in this study. Therefore, 
it is possible that also other ribotypes may be involved in severe 
CDI with lethal outcome. Our experience shows that offering the 
possibility to submit samples from patients with severe CDI to 
a specialised laboratory at no charge may help to collect more 
complete information.
In conclusion, the results presented here suggest that severe CDI 
is prevalent among hospitalised patients in Hesse. Severe CDI was 
associated with a high case fatality rate, especially in patients over 
70 years of age. Nine different C. difficile ribotypes were associated 
with severe CDI. Lethal infections were observed in association with 
RT 001, 017, and 027. This study underlines the need for further 
studies on molecular epidemiology of C. difficile.
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